Press release
December 22, 2016

Evonik ramps up production capacity for biomaterials

•  Facility expansion for the production of RESOMER® polymers in Birmingham 
    (Alabama, USA)
•  Part of a global expansion plan aimed at solidifying Evonik’s leadership in the 
    bioresorbable polymer market
•  Plan includes the opening of a second applied technology laboratory for 
    medical devices in Darmstadt in late 2016

Evonik is expanding its production facilities in Birmingham (Alabama, USA) and Darmstadt (Germany). This will create additional capacity for the production of biodegradable polymers marketed globally under the brand names RESOMER® and RESOMER® SELECT. These poly-lactic-glycolic-acid (PLGA) copolymers are primarily used to manufacture bioresorbable medical devices and controlled-release formulations for parenteral drug delivery.

“We expect the global demand for biodegradable polymers to continue to grow in the coming years,” explains Paul Spencer, Head of Biomaterials at Evonik’s Health Care Business Line. “With this in mind, we are currently investing to increase the capacity of our production facilities in order to serve our global customer base.”

The expansion will involve construction of a new building adjacent to Evonik’s existing facility in Birmingham. Besides greater production capacity, the project will also result in new production clean rooms and a laboratory for polymer contract research projects. Commissioning is slated for late 2018.

The expanded plant in Birmingham is the second investment to serve the growing market demand after the inauguration of the new manufacturing site in Darmstadt two years ago. The Darmstadt unit capacity will also be increased with the opening of a new production line. “By serving the market from two state-of-the-art locations, Evonik strengthens its role as a reliable partner for its customers and underpin its commitment to this market” adds Spencer.

Moreover, Evonik will open an applied technology laboratory in Darmstadt at the end of the year to support its customers in the medical device field. Its first facility of this kind was completed in 2015 in Shanghai (China). At these laboratories, customers receive prompt support for product development and training in the use of Evonik products.

Company information

Evonik, the creative industrial group from Germany, is one of the world leaders
in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik’s corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms. Evonik is active in over 100 countries around the world. In fiscal 2015 more than 33,500 employees generated sales of around €13.5 billion and an operating profit (adjusted EBITDA) of about €2.47 billion.

Evonik Industries has been producing specialty chemical products in the Greater China region (Mainland China, Hong Kong and Taiwan) since the late 1970’s; with wide-ranging trading relations already in place prior to this in the region. Evonik regards Greater China as one of the driving forces of the global economy and we consequently endeavor to grow our business in the region. The company now has around 3,000 employees in the Greater China region, the regional sales reached over €1.3 billion in 2015.


In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.